Occasional review: Influenza in COPD: Pathogenesis, prevention, and treatment

International Journal of COPD

Volumn 2, Issue 1, 2007, Pages 5-10

  Wesseling, Geertjan ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; COPD; Influenza; Neuraminidase inhibitors; Prevention; Treatment

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; ANTIVIRUS AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; INACTIVATED VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; OSELTAMIVIR; OXYGEN; PLACEBO; RIMANTADINE; SIALIDASE; SIALIDASE INHIBITOR; ZANAMIVIR;

ANTIBIOTIC RESISTANCE; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; EPIDEMIC; HIGH RISK PATIENT; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MORBIDITY; MORTALITY; NAUSEA; PANDEMIC; PATHOGENESIS; PRESCRIPTION; RESPIRATORY TRACT INFECTION; RETCHING; REVIEW; SYSTEMATIC REVIEW; VIRUS IMMUNITY; VIRUS TRANSMISSION; VOMITING;

AMANTADINE; ANTIVIRAL AGENTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; OSELTAMIVIR; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RIMANTADINE; ZANAMIVIR;

EID: 34250315817     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: 10.2147/copd.2007.2.1.5     Document Type: Review

References (36)

1. Aoki FY, Macleod MD, Paggiaro P, et al. 2003. Early administration of oseltamivir increases the benefit of influenza treatment. J Antimicrob Chemother, 51:123-9.
2. Beigel JH, Farrar J, Han AM, et al. 2005. Avian influenza A (H5NI) infection in humans. N Eng J Med, 353:1374-85.
3. Brundage LF. 2006. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis, 6:303-12.
4. Burge PS, Calverley PMA, Jones PW, et al. 2000. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ, 320:1297-303.
5. Freund B, Gravenstein S, Elliott M, et al. 1999. Zanamivir: a review of clinical safety. Drug Saf, 21:267-81.
6. Gorse GJ, O'Connor TZ, Young SL, et al. 2006. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest, 130:1109-16.
7. Gross PA, Hermogenes AW, Sacks HS, et al. 1995. The efficacy of influenza vaccine in elderly patients. Ann Intern Med, 123:518-23.
8. Hers JF. 1966. Disturbances of the ciliated epithelium due to influenza virus. Am Rev Respir Dis, 93(suppl): 162-77.
9. Jefferson TO, Demicheli V, Di Pietrantonj C, et al. 2006. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev, 3:CD001265.
10. Jones PW. 2004. Clinical effects of inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 1:167-70.
11. Leneva IA, Roberts N, Govorkova EA, et al. 2000. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is effective against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res, 48:101-15.
12. Mallia P, Johnston SL. 2006. How viral infections cause exacerbations of airway diseases. Chest, 130:1203-10.
13. Matrosovich MN, Matrosovich TY, Gray T, et al. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol, 78:12665--7.
14. Monto AS, Gravenstein S, Elliott M, et al. 2000. Clinical signs and symptoms predicting influenza infection. Arch Intern Med, 160:3243-7.
15. Monto AS, McKimm-Breschkin JL, Macken C, et al. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first three years of their use. Antimicrob Agents Chemother, 50:2395-402.
16. Moscona A. 2005. Neuraminidase inhibitors for influenza. N Eng J Med, 353:1363-73.
17. Nathan RA, Geddes D, Woodhead M. 2001. Management of influenza in patients with asthma or chronic obstructive pulmonary disease. Ann Allergy Asthma Immunol, 87:447-54.
18. [NHLBI] National Heart, Lung and Blood Institute. 2006. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Updated 2006 [online]. Accessed on 5 January 2007. URL: http://www.goldcopd.com.
19. Nichol KL, Baken L, Nelson A. 1999. Relation between influenza vaccination and out-patient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Annals Internal Med, 130:397-403.
20. Nichol KL, Wuorenma J, von Stenberg T. 1998. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Internal Med, 158:1769-76.
21. Nicholson KG, Aoki FY, Osterhaus AD, et al. 2000. Efficacy and safety of oseltamivir in the treatment of acute influenza: a randomised controlled trial. Lancet, 355:1845-50.
22. Poole PJ, Chacko E, Wood-Baker RWB, et al. 2006. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 1: CD002733.
23. Proud D, Chung-Wai C. 2006. Role of viral infections in asthma and chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 35:513-18.
24. Rohde G, Wiethage A, Borg I, et al. 2003. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalizations: a case-control study. Thorax, 58:37-42.
25. Seemungal TA, Harper-Owen R, Bhowmik A, et al. 2001. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 164:1618-23.
26. Simonsen L, Fukuda K, Schonberger LB, et al. 2000. The impact of influenza epidemics on hospitalizations. J Infect Dis, 181:831-7.
27. Stamboulian D, Bonvehi PE, Nacinovich FM, et al. 2000. Influenza. Infect Dis Clin North Am, 14:141-66.
28. Wedzicha JA. 2004. Role of viruses in exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 1:115-20.
29. Welliver R, Monto AS, Carewicz O, et al. 2001. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA, 285:748-54.
30. [WHO] World Health Organisation. 2005. Influenza vaccines: position paper. Wkly Epidemiol Rec, 80:279-87.
31. Wilkinson TMA, Donaldson GC, Johnston SL, et al. 2006. Respiratory syncytial virus, airway inflammation and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 173:871-6.
32. Williamson JC, Pegram PS. 2002. Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med, 1:85-90.
33. Wiselka M. 1994. Influenza: diagnosis, management and prophylaxis. BMJ, 308:1341-5.
34. Wongsurakiat P, Maranetra KN, Wasi C, et al. 2004. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination. Chest, 125:2011-20.
35. Zambon MC, Hayden FG. 2001. Global neuraminidase inhibitor susceptibility network. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res, 49:147-56.
36. Zambon MC. 1999. Epidemiology and pathogenesis of influenza. J Antimicrob Chemother, 44(suppl)B:3-9.